As of November 6, 2026, Revelation Biosciences, Inc. is a publicly traded company (Nasdaq: REVB); its largest reported holder is Sabby Management, LLC, with 9.6% on Schedule 13G of January 20, 2026. The largest insider holding is Zygmont Chester Stanley III, the chief financial officer, with 508,211 shares (74.4% of shares outstanding), per Form 4 of August 18, 2026 (Schedule 13G, January 20, 2026).
Is this your company?
About to sign with, pay or invest in Revelation Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Revelation Biosciences, Inc. a real, registered company?
- Revelation Biosciences, Inc. files with the SEC under CIK 1810560 (its SEC filings).
- Its shares are listed under the ticker REVB on Nasdaq (also REVBW) (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under REVELATION BIOSCIENCES, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-05-15).
Who are Revelation Biosciences, Inc.'s owners and officers?
Revelation Biosciences, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2026-05-15 | Armistice Capital, LLC | 7.8% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2026-01-20 | Sabby Management, LLC | 9.6% |
| Schedule 13G, 2025-11-14 | Armistice Capital, LLC | 9.99% |
Questions about who owns Revelation Biosciences, Inc.
Who owns Revelation Biosciences, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Revelation Biosciences, Inc.: Sabby Management, LLC (9.6%, Schedule 13G, filed 2026-01-20).
When did Sabby Management, LLC buy into Revelation Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sabby Management, LLC on this page is the Schedule 13G, filed 2026-01-20, reporting 9.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Revelation Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Revelation Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Revelation Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Revelation Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief financial officer: 508,211 shares (74.4% of shares outstanding), 208,073 held directly and 300,138 indirectly (Form 4, 2026-08-18).
- , the chief executive and a director: 422,814 shares (61.9% of shares outstanding) (Form 4, 2026-08-18).
- , a director: 44,839 shares (6.6% of shares outstanding) (Form 4, 2026-08-18).
- , a director: 44,769 shares (6.6% of shares outstanding) (Form 4, 2026-08-18).
- , a director: 44,169 shares (6.5% of shares outstanding) (Form 4, 2026-08-18).
Shares outstanding: 683,442 as of 2026-11-02, from the company's latest SEC cover page.
How much has Revelation Biosciences, Inc. raised?
Latest IPO step: Revelation Biosciences, Inc. amended its IPO registration (S-1/A, 2025-05-23).
IPO filings: S-1/A, 2025-05-23, S-1, 2025-05-20; ticker REVB on Nasdaq.
Keep reading
More on Revelation Biosciences, Inc. and the records around it.
Companies that share a holder
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/revelation-biosciences